What You Should Know
- Healthcare intelligence leader Health Catalyst, Inc. completed the sale of its mid-revenue cycle business, Vitalware, LLC, to Med-Metrix, LLC on July 31, 2026.
- The divestiture generated $147M in total cash consideration, subject to customary adjustments.
- Health Catalyst combined the net proceeds with cash on hand to fully repay and retire its credit facility, eliminating approximately $19M in annual GAAP interest expense.
- Capital and operational focus will pivot toward scaling Health Catalyst’s core healthcare intelligence platform, leveraging $2.8B in documented clinical and financial outcomes across 380+ client case studies.
- CEO Ben Albert stated that the company will pair 18 years of proprietary analytics with AI-driven decisioning tools to drive sustainable operational change for health systems.
Health Catalyst Divests Vitalware for $147M to Focus on AI Intelligence Layer
Health Catalyst has agreed to sell its mid-revenue cycle business unit, Vitalware, to Med-Metrix for $147M in cash. The transaction enables the healthcare intelligence company to exit non-core financial software and direct its engineering capital toward its core data platform and artificial intelligence roadmap.
While mid-revenue cycle tools—such as chargemaster management, price transparency, and charge capture—generate stable software revenue, managing ancillary financial products sits outside Health Catalyst’s core focus on clinical, operational, and consumer outcomes. By divesting Vitalware, which generated approximately $37 million in fiscal year 2025 revenue, the company concentrates resources on its primary analytics engine, which is built on 18 years of healthcare improvement data and $2.8 billion in documented outcomes.
Health Catalyst plans to deploy the net cash proceeds from the sale, along with existing liquidity, to fully repay and terminate its senior secured term loan facility. The facility carried an outstanding principal of approximately $160 million as of March 31, 2026. Clearing the obligation eliminates ongoing interest drag, strengthening the company’s balance sheet and increasing financial flexibility to back its long-term AI strategy.
Raymond James served as the exclusive financial advisor, and Latham & Watkins LLP served as legal counsel to Health Catalyst for the transaction. The acquisition by Med-Metrix remains subject to standard regulatory approvals and closing conditions.
“This is a big step forward for Health Catalyst,” said Ben Albert, CEO of Health Catalyst. “We are concentrating our business around the areas where we have the deepest conviction, and we plan to put the capital structure in place to back our long-term strategy. Vitalware is a great business, and we are pleased to have found a partner in Med-Metrix who is well positioned to carry it forward.”
